Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis

Company Overview

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $13.34 to $13.77
• 50-Day Range: $12.53 to $16.38
• 52-Week Range: $12.06 to $25.07
• Volume: 116,888 shs
• Average Volume: 1.45 million shs
• Market Capitalization: $1.15 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $36.20
• Consensus Rating: Moderate Buy

Syndax Pharmaceuticals Stock Analysis - MarketRank™

Syndax Pharmaceuticals scored higher than 74% of companies evaluated by MarketBeat, and ranked 243rd out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Syndax Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Syndax Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Syndax Pharmaceuticals are expected to decrease in the coming year, from ($3.72) to ($4.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Syndax Pharmaceuticals is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Syndax Pharmaceuticals is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Syndax Pharmaceuticals has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

23.46% of the float of Syndax Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Syndax Pharmaceuticals has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in Syndax Pharmaceuticals has recently decreased by 10.90%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Syndax Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Syndax Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.12

Percentage of Shares Shorted

23.46% of the float of Syndax Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Syndax Pharmaceuticals has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in Syndax Pharmaceuticals has recently decreased by 10.90%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.57

News Sentiment

Syndax Pharmaceuticals has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Syndax Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

Only 6 people have searched for SNDX on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Syndax Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $336,086.00 in company stock.

Percentage Held by Insiders

Only 4.10% of the stock of Syndax Pharmaceuticals is held by insiders.

SNDX Stock Analysis - Frequently Asked Questions

How have SNDX shares performed this year?

Syndax Pharmaceuticals' stock was trading at $13.22 at the start of the year. Since then, SNDX stock has increased by 3.9% and is now trading at $13.73.
View the best growth stocks for 2025 here.

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) released its quarterly earnings results on Monday, March, 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.79. The business earned $7.68 million during the quarter, compared to analyst estimates of $86.32 million.

When did Syndax Pharmaceuticals IPO?

Syndax Pharmaceuticals (SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Who are Syndax Pharmaceuticals' major shareholders?

Top institutional investors of Syndax Pharmaceuticals include Vanguard Group Inc. (5.72%), Wellington Management Group LLP (4.96%), Wellington Management Group LLP (4.92%) and Soleus Capital Management L.P. (2.92%). Insiders that own company stock include Michael A Metzger, Neil Gallagher, Dennis Podlesak, William Meury, Keith Katkin, Pierre Legault, Briggs Morrison and Peter Ordentlich.
View institutional ownership trends.

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Syndax Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 3/03/2025
• Today: 3/25/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SNDX
• CIK: 1395937
• Web: www.syndax.com
• Phone: (781) 419-1400
• Fax: 781-419-1420
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $36.20
• High Stock Price Target: $51.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: +170.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-209,360,000.00
• Net Margins: N/A
• Pretax Margin: -1,856.64%
• Return on Equity: -64.34%
• Return on Assets: -57.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.99
• Quick Ratio: 6.99

Sales & Book Value

• Annual Sales: $23.68 million
• Price / Sales: 48.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.53 per share
• Price / Book: 2.05

Miscellaneous

• Outstanding Shares: 86,024,000
• Free Float: 81,858,000
• Market Cap: $1.15 billion
• Optionable: Optionable
• Beta: 0.92